PharmaRadar360

PharmaRadar360

OncologyDrug intelligence

Tecentriq

Atezolizumab

PD-L1 immune checkpoint inhibitor. Developed by Roche. Clinical, regulatory, and source evidence are connected below.

Company
Roche
Target / MOA
PD-L1 路 CD274
Aliases
Tecentriq 路 MPDL3280A
Signals
22
Clinical trials
20
Approvals
2
Evidence sources
22

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialClinicalTrials.gov

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Phase 3 路 ACTIVE_NOT_RECRUITING 路 National Cancer Institute (NCI)

clinical trialClinicalTrials.gov

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Phase 2 路 ACTIVE_NOT_RECRUITING 路 National Cancer Institute (NCI)

clinical trialClinicalTrials.gov

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Phase 2 路 RECRUITING 路 Genentech, Inc.

Clinical trials

Key active studies

A focused view of recently updated studies 路 20 linked records.

Phase 3ACTIVE NOT RECRUITINGNCT02997228

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

National Cancer Institute (NCI) 路 Updated Mar 12, 2026

Phase 2ACTIVE NOT RECRUITINGNCT04334941

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI) 路 Updated Mar 12, 2026

Phase 2RECRUITINGNCT05968326

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Genentech, Inc. 路 Updated Mar 12, 2026

Phase 2ACTIVE NOT RECRUITINGNCT05411081

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

National Cancer Institute (NCI) 路 Updated Mar 12, 2026

Phase 1RECRUITINGNCT06287775

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI) 路 Updated Mar 12, 2026

Phase 2RECRUITINGNCT05001880

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

National Cancer Institute (NCI) 路 Updated Mar 12, 2026

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Mar 12, 202620FDAofficial 路 Latest Nov 17, 20252
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.